Developer docs
API playgroundTry for free, no card

Search company profiles

Ashvattha Therapeutics

Full company profile

uuid0000586

Namestring
Ashvattha Therapeutics
Legal namestring
Ashvattha Therapeutics
Websiteurl
avttx.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
precision nanomedicines, hydroxyl dendrimer therapeutics, ophthalmology drug development, neuroinflammation treatments, targeted drug delivery
Industry3 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmology Therapeutics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue Clinical Development
TypeSubscription Recurring
Description

Ashvattha Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with no products approved or commercially marketed. Operations are funded by equity financing from venture capital and strategic investors (Series B of $69M in April 2022, Series B Extension of up to $50M in January 2025). No product revenue is currently recognized.

avttx.com
2Licensing Royalties (Future)
TypeLicensing Royalties
Description

Future revenue stream from the exclusive licensing agreement with Huadong Medicine covering China and southeast Asia (Singapore, Malaysia). Huadong advances up to $30M for R&D and $15M for additional preclinical candidates and will pay Ashvattha a royalty of 10% of net sales of licensed products. This stream is contingent on commercial approval of licensed products in the territory.

avttx.com
3Strategic Partnership / Out-licensing (Future)
TypeLicensing Royalties
Description

Management has indicated openness to potential partnership or commercialization transactions for migaldendranib in major markets, leveraging the post-Phase 2 FDA alignment on pivotal trial design. Future revenue could include upfront payments, development milestones, and royalties from global pharma partners.

globenewswire.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OcuPair
Description

A novel dendrimer-hyaluronic acid hydrogel sealant for temporary corneal wound stabilization, referenced as an Ashvattha research program at ARVO 2020.

avttx.com
Core offering1 text field

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing precision nanomedicines based on its proprietary Hydroxyl Dendrimer (HD) platform, which targets ophthalmology, neurology and inflammatory disease indications. Its lead clinical candidate Migaldendranib (MGB) is a subcutaneous anti-VEGF nanomedicine for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), while OP-101 targets hyperinflammation and [18F]OP-801 is a PET imaging agent for neuroinflammation. The company is pre-revenue and funded by venture capital, with a regional licensing partnership with Huadong Medicine covering Asia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company whose offering is structured as a single core platform technology — the Hydroxyl Dendrimer (HD) Platform — plus a portfolio of clinical and preclinical module-style candidates built on top of it. The HD platform enables targeted, intracellular precision nanomedicines that traverse tissue barriers (including the blood-retinal barrier and blood-brain barrier) and selectively accumulate in activated/reactive inflammatory cells. Built on this platform are the lead clinical-stage candidate Migaldendranib (MGB, also referenced as D-4517.2 in earlier development) for ophthalmology (DME/nAMD); OP-101 (developed through subsidiary Orpheris) for hyperinflammation including severe COVID-19; the companion diagnostic PET tracer [18F]OP-801 (with the broader OP-801 imaging program) for neuroinflammation imaging; and the preclinical SPECT tracer 111In-D6-B483 for brain tumor imaging. The platform also extends into tissue-targeted variants — hepatocyte-targeted hydroxyl dendrimers (htHD) for liver diseases and bone-targeted hydroxyl dendrimers (btHD) for arthritis/bone disorders — making the portfolio a unified platform-plus-modules architecture in which each named product is a differentiated HD-conjugate or HD-imaging agent derived from the same underlying hydroxyl dendrimer chemistry exclusively licensed from Johns Hopkins University.

Product and service4 records
1Migaldendranib (MGB)
CategoryClinical-stage ophthalmology nanomedicine (subcutaneous anti-VEGF)
Description

First-in-class clinical-stage subcutaneous nanomedicine (hydroxyl dendrimer conjugated to a VEGFR/PDGFR tyrosine kinase inhibitor) in Phase 2 development for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). It crosses the blood-retinal barrier in regions of inflammation and selectively normalizes VEGF expression in activated macrophages, microglia, and hypoxic retinal pigment epithelial cells, with demonstrated 78.6% reduction in supplemental anti-VEGF injections in DME and 83.4% reduction in nAMD in a 40-week Phase 2 study, designed for once-monthly at-home self-administration via autoinjector.

2OP-101
CategoryClinical-stage nanomedicine for hyperinflammation / neuroinflammation
Description

Clinical-stage hydroxyl dendrimer therapeutic (HDT) created by conjugation of N-acetyl cysteine (NAC) to the hydroxyl dendrimer, selectively targeting reactive macrophages and microglia to shut down multiple hyperinflammation pathways (NFkB, JAK/STAT/MAPK) in conditions including severe COVID-19 and other viral/bacterial hyperinflammation. Developed initially through wholly-owned subsidiary Orpheris; Phase 2a PRANA study showed reduced risk of mechanical ventilation or death (18% vs 71% for placebo) and attenuated neuronal injury markers.

3[18F]OP-801 PET Imaging Agent
CategoryClinical-stage companion diagnostic / neuroimaging PET tracer
Description

Clinical-stage hydroxyl dendrimer-based PET imaging agent (radiolabeled with fluorine-18) developed as a companion diagnostic and pharmacodynamic biomarker for HD therapeutics. It crosses the blood-brain barrier in regions of neuroinflammation and is selectively (>95%) taken up by reactive microglia/macrophages in neurodegenerative diseases including ALS, Alzheimer's disease, Parkinson's disease, and multiple sclerosis; in Phase 1/2 study.

4111In-D6-B483 SPECT Imaging Agent
CategoryPreclinical SPECT imaging tracer for neuro-oncology
Description

Preclinical hydroxyl dendrimer SPECT tracer for selective imaging of brain tumors and metastases, extending the HD imaging platform into neuro-oncology applications. Preclinical data presented at the 2021 World Molecular Imaging Congress (WMIC).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Regeneron markets Eylea (aflibercept), the dominant intravitreal anti-VEGF therapy for nAMD and DME and the comparator in Ashvattha's Phase 2 trial; defines the standard of care migaldendranib must displace.

TypeDirect peer
Description

Ocular Therapeutix develops sustained-release intravitreal therapies for retinal diseases including DME and wet AMD, with comparable clinical-stage ophthalmology pipeline targeting reduced treatment burden.

TypeEmerging player
Description

AsclepiX Therapeutics is a clinical-stage ophthalmology biotech previously led by new Ashvattha Interim CEO Robert Dempsey, focused on novel peptide therapeutics for retinal diseases; a relevant emerging peer given shared leadership DNA and overlapping ophthalmology focus.

4Huadong Medicine
TypeOthers
Description

Huadong Medicine is Ashvattha's exclusive Asia licensee and lead investor in the 2022 Series B, controlling China and Southeast Asia rights to the HD pipeline and serving as both a strategic partner and a relevant comparator for BD economics in Asian pharma.

TypeDirect peer
Description

Adverum develops gene therapies for wet AMD and DME, directly competing with Ashvattha in next-generation ophthalmology therapeutics targeting anti-VEGF pathways with novel delivery modalities.

TypeDirect peer
Description

REGENXBIO develops AAV gene therapies (e.g., ABTICIPARVOVEC) for wet AMD and DME aimed at reducing anti-VEGF injection burden, directly competitive with migaldendranib's value proposition of decreasing treatment frequency in retinal disease.

TypeDirect peer
Description

Kodiak Sciences develops antibody biopolymer conjugates for retinal diseases including DME and nAMD, making it one of the closest direct comparables to Ashvattha's migaldendranib in the subcutaneous/intravitreal anti-VEGF space with Phase 3-stage assets.

8Graybug Vision
TypeEmerging player
Description

Graybug Vision develops sustained-release microparticle formulations for wet AMD and other ocular diseases, another emerging retinal-disease biotech pursuing reduced injection frequency with novel delivery technology.

9TearClear
TypeEmerging player
Description

TearClear is an ophthalmology startup previously led by Ashvattha's new Interim CEO Robert Dempsey, developing novel ocular drug delivery; a relevant thematic peer given shared leadership and ophthalmology focus.

TypeBroad incumbent
Description

Genentech/Roche markets Lucentis (ranibizumab) and Vabysmo (faricimab), the latter a bispecific anti-VEGF/Ang-2 approved for nAMD and DME that materially raises the competitive bar for subcutaneous entrants.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ashvattha Therapeutics

Ophthalmology Therapeuticsavttx.com

Ashvattha Therapeutics firmographics

Firmographics
Name
Ashvattha Therapeutics
Legal name
Ashvattha Therapeutics
Website
https://avttx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Ashvattha Therapeutics industry classification

Industry
Product category
Ophthalmology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Precision nanomedicines
  • Hydroxyl dendrimer therapeutics
  • Ophthalmology drug development
  • Neuroinflammation treatments
  • Targeted drug delivery

Where Ashvattha Therapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Markets served

Ashvattha Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue Clinical Development: Ashvattha Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with no products approved or commercially marketed. Operations are funded by equity financing from venture capital and strategic investors (Series B of $69M in April 2022, Series B Extension of up to $50M in January 2025). No product revenue is currently recognized.
  2. Licensing Royalties (Future): Future revenue stream from the exclusive licensing agreement with Huadong Medicine covering China and southeast Asia (Singapore, Malaysia). Huadong advances up to $30M for R&D and $15M for additional preclinical candidates and will pay Ashvattha a royalty of 10% of net sales of licensed products. This stream is contingent on commercial approval of licensed products in the territory.
  3. Strategic Partnership / Out-licensing (Future): Management has indicated openness to potential partnership or commercialization transactions for migaldendranib in major markets, leveraging the post-Phase 2 FDA alignment on pivotal trial design. Future revenue could include upfront payments, development milestones, and royalties from global pharma partners.

Go-to-market motion3 records

Ashvattha Therapeutics product offering

Product offering

Core offering

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing precision nanomedicines based on its proprietary Hydroxyl Dendrimer (HD) platform, which targets ophthalmology, neurology and inflammatory disease indications. Its lead clinical candidate Migaldendranib (MGB) is a subcutaneous anti-VEGF nanomedicine for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), while OP-101 targets hyperinflammation and [18F]OP-801 is a PET imaging agent for neuroinflammation. The company is pre-revenue and funded by venture capital, with a regional licensing partnership with Huadong Medicine covering Asia.

Product overview

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company whose offering is structured as a single core platform technology — the Hydroxyl Dendrimer (HD) Platform — plus a portfolio of clinical and preclinical module-style candidates built on top of it. The HD platform enables targeted, intracellular precision nanomedicines that traverse tissue barriers (including the blood-retinal barrier and blood-brain barrier) and selectively accumulate in activated/reactive inflammatory cells. Built on this platform are the lead clinical-stage candidate Migaldendranib (MGB, also referenced as D-4517.2 in earlier development) for ophthalmology (DME/nAMD); OP-101 (developed through subsidiary Orpheris) for hyperinflammation including severe COVID-19; the companion diagnostic PET tracer [18F]OP-801 (with the broader OP-801 imaging program) for neuroinflammation imaging; and the preclinical SPECT tracer 111In-D6-B483 for brain tumor imaging. The platform also extends into tissue-targeted variants — hepatocyte-targeted hydroxyl dendrimers (htHD) for liver diseases and bone-targeted hydroxyl dendrimers (btHD) for arthritis/bone disorders — making the portfolio a unified platform-plus-modules architecture in which each named product is a differentiated HD-conjugate or HD-imaging agent derived from the same underlying hydroxyl dendrimer chemistry exclusively licensed from Johns Hopkins University.

Differentiator

Problem solved

Functional benefit

Brands

  • OcuPair: A novel dendrimer-hyaluronic acid hydrogel sealant for temporary corneal wound stabilization, referenced as an Ashvattha research program at ARVO 2020.

Products and services

  • Migaldendranib (MGB) First-in-class clinical-stage subcutaneous nanomedicine (hydroxyl dendrimer conjugated to a VEGFR/PDGFR tyrosine kinase inhibitor) in Phase 2 development for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). It crosses the blood-retinal barrier in regions of inflammation and selectively normalizes VEGF expression in activated macrophages, microglia, and hypoxic retinal pigment epithelial cells, with demonstrated 78.6% reduction in supplemental anti-VEGF injections in DME and 83.4% reduction in nAMD in a 40-week Phase 2 study, designed for once-monthly at-home self-administration via autoinjector.
  • OP-101 Clinical-stage hydroxyl dendrimer therapeutic (HDT) created by conjugation of N-acetyl cysteine (NAC) to the hydroxyl dendrimer, selectively targeting reactive macrophages and microglia to shut down multiple hyperinflammation pathways (NFkB, JAK/STAT/MAPK) in conditions including severe COVID-19 and other viral/bacterial hyperinflammation. Developed initially through wholly-owned subsidiary Orpheris; Phase 2a PRANA study showed reduced risk of mechanical ventilation or death (18% vs 71% for placebo) and attenuated neuronal injury markers.
  • [18F]OP-801 PET Imaging Agent Clinical-stage hydroxyl dendrimer-based PET imaging agent (radiolabeled with fluorine-18) developed as a companion diagnostic and pharmacodynamic biomarker for HD therapeutics. It crosses the blood-brain barrier in regions of neuroinflammation and is selectively (>95%) taken up by reactive microglia/macrophages in neurodegenerative diseases including ALS, Alzheimer's disease, Parkinson's disease, and multiple sclerosis; in Phase 1/2 study.
  • 111In-D6-B483 SPECT Imaging Agent Preclinical hydroxyl dendrimer SPECT tracer for selective imaging of brain tumors and metastases, extending the HD imaging platform into neuro-oncology applications. Preclinical data presented at the 2021 World Molecular Imaging Congress (WMIC).

Companies that use Ashvattha Therapeutics

Customer profile

Ideal customer profiles2 records

Ashvattha Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ashvattha Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Ashvattha Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the dominant intravitreal anti-VEGF therapy for nAMD and DME and the comparator in Ashvattha's Phase 2 trial; defines the standard of care migaldendranib must displace.
  • Genentech (Roche): Genentech/Roche markets Lucentis (ranibizumab) and Vabysmo (faricimab), the latter a bispecific anti-VEGF/Ang-2 approved for nAMD and DME that materially raises the competitive bar for subcutaneous entrants.

Direct peers

  • Ocular Therapeutix: Ocular Therapeutix develops sustained-release intravitreal therapies for retinal diseases including DME and wet AMD, with comparable clinical-stage ophthalmology pipeline targeting reduced treatment burden.
  • Adverum Biotechnologies: Adverum develops gene therapies for wet AMD and DME, directly competing with Ashvattha in next-generation ophthalmology therapeutics targeting anti-VEGF pathways with novel delivery modalities.
  • REGENXBIO: REGENXBIO develops AAV gene therapies (e.g., ABTICIPARVOVEC) for wet AMD and DME aimed at reducing anti-VEGF injection burden, directly competitive with migaldendranib's value proposition of decreasing treatment frequency in retinal disease.
  • Kodiak Sciences: Kodiak Sciences develops antibody biopolymer conjugates for retinal diseases including DME and nAMD, making it one of the closest direct comparables to Ashvattha's migaldendranib in the subcutaneous/intravitreal anti-VEGF space with Phase 3-stage assets.

Emerging players

  • AsclepiX Therapeutics: AsclepiX Therapeutics is a clinical-stage ophthalmology biotech previously led by new Ashvattha Interim CEO Robert Dempsey, focused on novel peptide therapeutics for retinal diseases; a relevant emerging peer given shared leadership DNA and overlapping ophthalmology focus.
  • Graybug Vision: Graybug Vision develops sustained-release microparticle formulations for wet AMD and other ocular diseases, another emerging retinal-disease biotech pursuing reduced injection frequency with novel delivery technology.
  • TearClear: TearClear is an ophthalmology startup previously led by Ashvattha's new Interim CEO Robert Dempsey, developing novel ocular drug delivery; a relevant thematic peer given shared leadership and ophthalmology focus.

Others

  • Huadong Medicine: Huadong Medicine is Ashvattha's exclusive Asia licensee and lead investor in the 2022 Series B, controlling China and Southeast Asia rights to the HD pipeline and serving as both a strategic partner and a relevant comparator for BD economics in Asian pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ashvattha Therapeutics social profiles

Digital presence

Ashvattha Therapeutics compliance and trust

Trust signal

Compliance1 record

Ashvattha Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ashvattha Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Ashvattha Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ashvattha Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ashvattha Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ashvattha Therapeutics

What does Ashvattha Therapeutics do?

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing precision nanomedicines based on its proprietary Hydroxyl Dendrimer (HD) platform, which targets ophthalmology, neurology and inflammatory disease indications. Its lead clinical candidate Migaldendranib (MGB) is a subcutaneous anti-VEGF nanomedicine for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), while OP-101 targets hyperinflammation and [18F]OP-801 is a PET imaging agent for neuroinflammation. The company is pre-revenue and funded by venture capital, with a regional licensing partnership with Huadong Medicine covering Asia.

Is Ashvattha Therapeutics a public or private company?

Ashvattha Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ashvattha Therapeutics founded?

Ashvattha Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Ashvattha Therapeutics based?

Ashvattha Therapeutics is headquartered in Redwood City, United States, in the North America region.

How does Ashvattha Therapeutics make money?

Three revenue lines are on record. Pre-revenue Clinical Development is the primary driver. The others are licensing Royalties (Future) and strategic Partnership / Out-licensing (Future).

Who are Ashvattha Therapeutics's main competitors?

Broad incumbents on record are Regeneron Pharmaceuticals and Genentech (Roche). Direct peers are Ocular Therapeutix, Adverum Biotechnologies, REGENXBIO and Kodiak Sciences. Emerging players are AsclepiX Therapeutics, Graybug Vision and TearClear. Huadong Medicine is listed as an others.

Does Ashvattha Therapeutics have an API?

No public API is recorded for Ashvattha Therapeutics.

What industry is Ashvattha Therapeutics in?

Ashvattha Therapeutics's product category is Ophthalmology Therapeutics. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarAshvattha Therapeutics Announces Investor and Conference PresentationsAshvattha Therapeutics announced presentations of Phase 2 results for migaldendranib (MGB), a subcutaneous treatment for diabetic macular edema and neovascular AMD. The trial showed stable vision and fluid, with no serious adverse events, and the company plans a Phase 2b/3 trial in 2027.Business Wire BlogAshvattha Therapeutics Announces Investor and Conference PresentationsAshvattha Therapeutics announced presentations of Phase 2 trial results for migaldendranib (MGB), a subcutaneous treatment for diabetic macular edema and neovascular age-related macular degeneration. The trial showed stable vision and fluid, with no serious adverse events, supporting advancement to Phase 2b. The company plans a Phase 2b/3 study in DME patients for 2027.Ophthalmology TimesPresident and CEO of Ashvattha Therapeutics talks about the company's unique nanomedicine technologyAshvattha Therapeutics is advancing its D-4517.2 nanomedicine technology, which targets wet AMD and DME through systemic administration to eliminate the need for intravitreal injections. Initial clinical data showed that a single subcutaneous dose stabilized fluid in 11 out of 12 patients for at least two weeks, with the company currently conducting trials to prolong treatment intervals. The company also plans to evaluate an oral dosage form and expand its platform into neurodegenerative diseases like Alzheimer's and Parkinson's.Ophthalmology TimesAshvattha Therapeutics secures $50M in financing to advance clinical trialsAshvattha Therapeutics has secured up to $50 million in Series B financing from investors Tribe Capital and Natural Capital to support its clinical development pipeline. The funds will be used to complete an ongoing Phase 2 trial for its proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME, as well as a Phase 1/2 neuroinflammation trial. Interim results indicate the therapy reduces the need for supplemental aflibercept injections, validating the company's subcutaneous delivery approach.The Pharma LetterAshvattha TherapeuticsAshvattha Therapeutics secured up to $50 million in Series B financing led by Tribe Capital to support its Phase II ophthalmology and Phase I/II neuroinflammation trials. Interim results for its lead candidate, migaldendranib, demonstrated a substantial reduction in the need for supplemental aflibercept while maintaining visual acuity in patients with wet AMD and diabetic macular edema.Ophthalmology TimesPositive interim phase 2 results for MGBAshvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a subcutaneous nanomedicine targeting retinal vascular diseases like wet AMD and DME. The study data showed significant reductions in anti-VEGF treatment burden and improvements in visual acuity with no serious adverse events reported. These findings were presented at the 2025 Association for Research in Vision and Ophthalmology annual meeting.Business Wire BlogAshvattha Therapeutics Announces Presentations Highlighting Mechanism of Action for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular DegenerationAshvattha Therapeutics announced that it will present clinical trial results for its investigational nanomedicine, migaldendranib (MGB), at the Association for Research in Vision and Ophthalmology (ARVO) conference. The Phase 2 trial data demonstrated that a single subcutaneous dose of MGB stabilized retinal fluid and visual acuity in patients with diabetic macular edema and neovascular age-related macular degeneration without requiring supplemental intravitreal injections. The company plans to initiate a Phase 2b/3 trial later this year following an agreement with the FDA.GlobeNewswireAshvattha Therapeutics to Showcase Topline Phase 2 Data and Recent FDA Alignment at Upcoming Investor and Ophthalmology MeetingsAshvattha Therapeutics announced it will present 40-week topline Phase 2 data for migaldendranib (MGB), its first-in-class subcutaneous nanomedicine for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), at upcoming ophthalmology conferences including FLORetina in Florence and Ophthalmology Innovation Summit in San Diego. The company also disclosed FDA alignment on its Phase 2b/3 trial design, providing a clear regulatory pathway for two well-controlled studies under a single protocol. Leadership will attend investor meetings including the Jefferies Global Healthcare Conference in London from November 17-19, 2025.FierceBiotechChutes & Ladders—Cabaletta corrals cell therapy Legend as commercial chiefThis article reports on a series of recent executive leadership changes across multiple biotechnology and pharmaceutical companies, including appointments at Cabaletta Bio, Ashvattha Therapeutics, Alentis Therapeutics, Geron Corporation, and others. Key moves include Steve Gavel becoming CCO at Cabaletta Bio, Robert Dempsey taking over as interim CEO at Ashvattha Therapeutics, and Mark Pruzanski assuming the CEO role at Alentis Therapeutics. These hires reflect strategic adjustments in commercialization, clinical development, and corporate governance within the sector.GlobeNewswireAshvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal ProgramAshvattha Therapeutics appointed ophthalmology veteran Robert J. Dempsey as Interim CEO following positive Phase 2 results for its nanomedicine candidate migaldendranib in treating diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The Phase 2 trial demonstrated strong safety and efficacy, including an 83.4% reduction in supplemental anti-VEGF injections for nAMD patients and 78.6% for DME patients, with no treatment-related serious adverse events. The FDA has endorsed Ashvattha's Phase 2b/3 clinical design and agreed to conduct two studies under a single protocol, providing a clear regulatory pathway toward potential approval and commercialization.